NovaBiotics Ltd is a clinical-stage biotechnology company.
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®).NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 3, 2016 | Series Unknown | £3M | 1 | — | — | Detail |
Jun 1, 2009 | Angel | £1.10M | 1 | Aurora Private Equity | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Aurora Private Equity | Yes | Angel |
Grampian Biopartners | — | Series Unknown |